Request Your Free White Paper Now:

"Beyond cfDNA: Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection"

Liquid biopsies have shown great promise in the clinical management of cancer patients.

Despite considerable advances in molecular profiling, there remains a high unmet medical need for early cancer detection. The analysis of cell-free DNA (cfDNA) presents new opportunities to analyze low-expression biomarkers due to the high signal-to-noise ratio; to detect cancer early; to distinguish cancer from benign conditions; and to identify fast- and slow-growing cancers.

Liquid biopsy markers are advantageous because they can be used to assess overall prognosis, response to therapy, and likelihood of relapse or progression. This insightful whitepaper summarizes four peer-reviewed articles that explore the combination of exosomal RNA (exoRNA) and cfDNA in cancer diagnosis and treatment.

• Combining plasma exoRNA plus cfDNA increases mutation detection in early-stage cancer patients
• Combination of exoRNA/DNA and cfDNA results in higher sensitivity and specificity than using cfDNA alone for activating EGFR mutations
• A single qPCR-based test can be used to interrogate mutations within EGFR using exoRNA/DNA and cfDNA derived from patient plasma with NCSLC
• Testing for plasma exoRNA is as sensitive as cfDNA in detecting mutations in advanced cancer patients

Offered Free by: Bio-Techne
See All Resources from: Bio-Techne